Abstract
Clear regulatory planning during the early stages of product development is essential to develop a focused regulatory strategy that can be presented to national regulatory authorities (NRAs). NRAs regulate pharmaceutical products to enable patient access to high-quality, safe, and effective products, and restrict access to those products that are unsafe or have limited clinical use. Regulatory procedures affect all stages of biomedical product development. Detailed safety review during research and development stages, regulatory approval, and legal registration are necessary stages of product development. When appropriately implemented, regulation ensures public health benefit and the safety of patients, healthcare workers, and the broader community. Therefore, it is critical that developers of biomedical products (drugs, biologics, devices, in vitro diagnostics, or some combination) possess the knowledge and awareness of the regulatory challenges and opportunities to expedite the development of safe and effective products in a cost-effective manner.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.